|Dr. Peter M. Hecht Ph.D.||Co-Founder, Chief Exec. Officer and Director||108.06k||2.76M||53|
|Mr. Thomas Graney||CFO & Sr. VP of Fin. & Corp. Strategy||N/A||N/A||52|
|Dr. Mark G. Currie Ph.D.||Chief Scientific Officer, Pres of R&D and Sr. VP||763.04k||6.08M||62|
|Ms. Halley E. Gilbert Esq.||Sr. VP, Chief Legal Officer & Sec.||711.04k||315.6k||47|
|Mr. Thomas A. McCourt||Chief Commercial Officer and Sr. VP of Marketing & Sales||731.04k||N/A||60|
Ironwood Pharmaceuticals, Inc., a commercial biotechnology company, engages in the research, development, and commercialization of human therapeutic products. The company markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation (CIC) under the LINZESS name in the United States and Constella name in the European Union; and lesinurad for the treatment of hyperuricemia associated with uncontrolled gout under ZURAMPIC and DUZALLO names. It has collaboration agreements with Allergan plc and AstraZeneca AB to develop and commercialize linaclotide for the treatment of IBS-C, CIC, and other GI conditions in North America, China, Hong Kong, and Macau; and license agreement with Astellas Pharma Inc. to develop and commercialize linaclotide for the treatment of IBS-C, chronic constipation, and other GI conditions in Japan. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was founded in 1998 and is headquartered in Cambridge, Massachusetts.
Ironwood Pharmaceuticals, Inc.’s ISS Governance QualityScore as of September 1, 2017 is 9. The pillar scores are Audit: 2; Board: 9; Shareholder Rights: 8; Compensation: 7.